Evidence map›Paper›PMID 30972901›Full record

ArticleCancer science2019

Performance of Oncomine Fusion Transcript kit for formalin-fixed, paraffin-embedded lung cancer specimens.

Kazuko Sakai, Tatsuo Ohira, Jun Matsubayashi, Azusa Yoneshige, Akihiko Ito, Tetsuya Mitsudomi, Toshitaka Nagao, Emi Iwamatsu, Jin Katayama, Norihiko Ikeda and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Detection ofFrontiers in cell and developmental biology · 2022
    Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Kazuko SakaiDepartment of Genome Biology, Kindai University Faculty of Medicine, Osaka, Japan.
Tatsuo OhiraDepartment of Surgery, Tokyo Medical University, Tokyo, Japan.
Jun MatsubayashiDepartment of Anatomic Pathology, Tokyo Medical University, Tokyo, Japan.
Azusa YoneshigeDepartment of Pathology, Kindai University Faculty of Medicine, Osaka, Japan.
Akihiko ItoDepartment of Pathology, Kindai University Faculty of Medicine, Osaka, Japan.
Tetsuya MitsudomiDepartment of Thoracic Surgery, Kindai University Faculty of Medicine, Osaka, Japan.
Toshitaka NagaoDepartment of Anatomic Pathology, Tokyo Medical University, Tokyo, Japan.
Emi IwamatsuLife Technologies Japan Ltd, Tokyo, Japan.
Jin KatayamaDiagnostic Partnering, Clinical Sequencing Division, Thermo Fisher Scientific, Tokyo, Japan.
Norihiko IkedaDepartment of Surgery, Tokyo Medical University, Tokyo, Japan.
Kazuto NishioDepartment of Genome Biology, Kindai University Faculty of Medicine, Osaka, Japan.ORCID https://orcid.org/0000-0002-8275-0846
Kindai University · JPTokyo Medical University · JPJapan Lifeline (Japan) · JPThermo Fisher Scientific (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gene fusions play an important role in the carcinogenesis of lung adenocarcinoma. The recent association of four oncogenic driver genes, ALK, ROS1, RET, and NTRK1, as lung tumor predictive biomarkers has increased the need for precision medicine. We used formalin-fixed, paraffin-embedded tissue samples of non-small cell lung cancer from 150 EGFR mutation-negative cases and 10 fusion status-known cases and compared the performance of the Oncomine Dx Fusion Transcript Test (ODxFT) with FISH break-apart for the detection of ALK, RET, and ROS1 fusion genes. RNA was extracted from the paraffin-embedded tissue samples with or without macrodissection under hematoxylin and eosin staining, and the ALK fusion gene was independently determined using these assays. Fusion detection analyses were successfully carried out using ODxFT in 150 cases, with only one invalid case. ALK fusion genes were detected at a frequency of 7.3% (11/150) in the lung cancer specimens. Concordance rate between the ODxFT and ALK-FISH analyses was 99.3% (148/149). Sensitivity and specificity were 91.7% and 99.3%, respectively. All the samples with a known fusion status were accurately matched between the two assays. Our results show a high concordance rate between the ODxFT and ALK-FISH analyses. ODxFT was thus validated as an effective method for detecting clinically significant ALK fusion genes in paraffin-embedded tissue samples.

Indexed as

Anaplastic Lymphoma KinaseBiomarkers, TumorFormaldehydeHumansIn Situ Hybridization, FluorescenceLung NeoplasmsMutationOncogene Proteins, FusionParaffin EmbeddingReproducibility of ResultsSpecimen HandlingTissue FixationALK protein, humanAnaplastic Lymphoma KinaseBiomarkers, TumorFormaldehydeOncogene Proteins, FusionALK fusion genecompanion diagnosisFISHnext-generation sequencernon-small cell lung cancer

Identifiers

PMID30972901
PMCPMC6549924
OpenAlexW2936168176

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.